Theravance Biopharma Inc (NASDAQ:TBPH) – Stock analysts at Svb Leerink issued their Q2 2020 EPS estimates for shares of Theravance Biopharma in a research note issued on Wednesday, May 8th. Svb Leerink analyst G. Porges forecasts that the biopharmaceutical company will post earnings per share of ($0.89) for the quarter. Svb Leerink also issued estimates for Theravance Biopharma’s Q3 2020 earnings at ($0.84) EPS and Q4 2020 earnings at ($0.91) EPS.
Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.14). The firm had revenue of $5.34 million during the quarter, compared to analysts’ expectations of $16.45 million. Theravance Biopharma had a negative return on equity of 2,632.27% and a negative net margin of 388.61%.
TBPH stock opened at $21.37 on Monday. The firm has a market capitalization of $1.20 billion, a PE ratio of -5.36 and a beta of 1.68. Theravance Biopharma has a 1 year low of $20.55 and a 1 year high of $35.48.
In related news, SVP Sharathchandra S. Hegde sold 9,033 shares of Theravance Biopharma stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $24.71, for a total transaction of $223,205.43. Following the transaction, the senior vice president now directly owns 270,134 shares in the company, valued at $6,675,011.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.60% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC lifted its position in Theravance Biopharma by 5.7% during the first quarter. Parametric Portfolio Associates LLC now owns 21,121 shares of the biopharmaceutical company’s stock valued at $479,000 after purchasing an additional 1,139 shares in the last quarter. Amundi Pioneer Asset Management Inc. lifted its position in Theravance Biopharma by 34.1% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 5,500 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,400 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in Theravance Biopharma during the fourth quarter valued at $42,000. NJ State Employees Deferred Compensation Plan lifted its position in Theravance Biopharma by 6.9% during the first quarter. NJ State Employees Deferred Compensation Plan now owns 31,142 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 2,000 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in Theravance Biopharma by 21.9% during the first quarter. DekaBank Deutsche Girozentrale now owns 11,700 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 2,100 shares in the last quarter. Institutional investors own 85.03% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Recommended Story: Why is Cost of Capital Important?
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.